{
    "nct_id": "NCT04134728",
    "official_title": "A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors",
    "inclusion_criteria": "Key inclusion criteria:\n\n* >=18 years of age\n* Has had RA for >=6 months and was not diagnosed before 16 years of age\n* Has active disease, as defined by having both:*\n\n  * >=6/68 tender/painful joints (tender joint count [TJC]), and\n  * >=6/66 swollen joints (swollen joint count [SJC])\n* Has had an inadequate response despite currently taking at least one and at the most two concomitant csDMARDs for at least 12 weeks, from the following:\n\n  * Methotrexate (MTX)\n  * Hydroxychloroquine or chloroquine\n  * Sulfasalazine\n  * Leflunomide\n  * Bucillamine\n  * Iguratimod\n  * Tacrolimus\n* Has had inadequate response to at least one bDMARD at an approved dose and/or at least one JAK inhibitors at an approved dose. In both cases this may be with or without combination with a csDMARD.\n\n  * If surgical treatment of a joint has been performed, that joint cannot be counted in the TJC or SJC.\n\nKey exclusion criteria:\n\n* Has had any active and/or recurrent infections (excluding recurrent fungal infections of the nail bed) or has required management of acute or chronic infections.\n* Has received prior treatment with an antagonist of GM-CSF or its receptor.\n* Has known infection with human immunodeficiency virus (HIV) or current acute or chronic hepatitis B and/or hepatitis C.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}